33 results about "CD86" patented technology

The invention relates to the field of cell biology, and particularly relates to a preparation method of a pancreatic cancer-related antigen-loaded polypeptide, which is characterized in that factors such as GM-CSF, IL-4, IFN-gamma, TNF-alpha, IL-1beta, IL-6, PGE2, Poly I: C, R848 and the like are added to promote mononuclear cells to be activated into DC cells, pancreatic cancer PANC-1, MIA PaCa-2, BxPC-3, KP4 and SW1990HM antigens are loaded, and not only is DC cell maturation promoted, but also pancreatic cancer-related antigens are loaded. The positive rate of CD83 + CD86 of the DC cells cultured by the method is 94.16%, and the secretion amount of IL-12p70 in a cell supernatant is (645.38 + / -36.49) pg / mL. By adopting the culture method disclosed by the invention, the maturation rate of the DC cells can be improved while the DC cells are activated, so that the culture method for promoting the maturation and amplification of the DC cells loaded with the pancreatic cancer antigen is achieved.

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

The invention relates to application of beta-glucan in preparation of a preparation for reducing the expression quantity of related genes of skin extracellular matrix inflammation. The structure of the beta-glucan is formed by connecting structural units. The invention also provides a biomarker, the biomarker is a gene related to skin extracellular matrix inflammation, and the gene comprises any one or a combination of at least two of IL1A, IL1B, IL1R1, IL1RAP, IL6, NFKB2, FOSB, FOSL1, JUN, JUND, CCL2, PTGS2, MMP10, MMP12, MMP13, CXCL8, CD86, PLAU, GADD45A, TNFSF18, TNFRSF10B, TNFRSF12A, TNFRSF14 or TNFRSF21.

The application discloses an antigen-engineered nanovesicle vaccine (AN-FV) and a preparation method and application thereof. The vaccine is formed by fusion of vesicles of tumor cell membranes obtained by pretreatment of functionalized nanometer preparations and vesicles of mature dendritic cell membranes; the functionalized nanometer preparations contain autophagy inhibiting siRNA and an immunogenicity enhancer, and can synergistically improve MHC-I expression of tumor cells and antigen immunogenicity. The vaccine of the application simultaneously presents high-density MHC-I-antigen peptide complexes and CD80 / CD86 costimulatory molecules on the surface of a single particle, simulates an immune synapse in a nanometer scale, and thus efficiently activates tumor-specific T cells. The vaccine integrates antigen source engineering, physiologicalization of costimulatory signals and nanometer platform integration, and provides a new scheme for overcoming the treatment bottleneck of immune "cold" tumors such as pancreatic cancer.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The application relates to the field of biological medicines, and discloses a tumor vaccine containing a polysaccharide adjuvant and application thereof. The tumor vaccine formula comprises, in terms of mass fractions, 100 parts of WT1-CM-betaG NPs, 10 parts of astragalus polysaccharide, 5 parts of quillaja saponin and 1 part of a TLR agonist. The WT1-CM-betaG NPs comprise, in terms of mass fractions, 10 parts of a WT1 polypeptide combination, 50 parts of carboxymethylated beta-glucan nanoparticles CM-betaG NPs, 10 parts of EDC and 6 parts of NHS. The WT1 polypeptide is covalently connected to the carboxymethylated beta-glucan nanoparticles through chemical coupling, and then cooperates with the adjuvant, has a synergistic effect on improving the ability of stimulating DC maturation (high expression of CD80 / CD86 / MHC-II) and improving the secretion of key Th1 type cytokine IL-12p70, can improve the antitumor effect, and has a wide application in treating WT1 positive tumors.

Provided herein are particles containing a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors such as lentiviral vectors containing the same, cells containing the same, and methods for using the same. The particle may be a lentiviral particle that displays a fusion molecule containing a) the CD58 extracellular domain or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) the CD80 or CD86 extracellular domain or a functional fragment thereof, and a viral glycoprotein (G protein) on the surface of the particle.

This invention belongs to the field of biomedical technology, specifically relating to the application of crizotinib in inducing tolerant dendritic cells (tDCs). This invention provides the application of crizotinib in inducing tolerant dendritic cells. This invention discovers that crizotinib can act as a highly effective inducer of tDCs, significantly inhibiting the activated state of DCs, suppressing their maturation function, reducing their immunostimulatory capacity, and thus inhibiting T cell activation, thereby exerting a therapeutic effect in immune diseases such as GVHD. The inhibitory effects of crizotinib on DCs in this invention include reducing the expression of maturation markers CD80, CD40, and CD86. The crizotinib used in this invention is an FDA-approved ALK / ROS1 inhibitor, primarily used for the treatment of non-small cell lung cancer. This invention discovers its application in immunotherapy, realizing the repurposing of an existing drug, and has significant economic value.

The application relates to the field of immunology, and provides an application of silk sericin and silk polypeptide, researches on extraction and purification methods of silk sericin and polypeptide, finds that the protein and polypeptide can promote maturation of dendritic cells, enhance expression of MHCII and CD86 on the cell surface, enhance antigen presentation capacity, and stimulate lymphocyte T cell proliferation in cooperation with the dendritic cells; researches on a preparation method of nanoemulsion vaccine prepared by taking the silk sericin and polypeptide as an adjuvant and antigens, and detection finds that the silk sericin and polypeptide can improve the immune activation efficiency of the vaccine, obviously enhance the antigen-specific acquired immune response level in the body, and effectively inhibit the virus infection of the body and the replication level of the virus, so that the purpose of enhancing the vaccine in preventing or treating diseases is achieved.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and / or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and / or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

The application discloses a PGPC / CpG combined adjuvant and a method and application thereof for improving the efficiency of a type I dendritic cell anti-tumor vaccine, and belongs to the technical field of biotechnology. The method for improving the efficiency of the type I dendritic cell anti-tumor vaccine by using the PGPC / CpG combined adjuvant disclosed by the application stimulates cDC1 by using the PGPC / CpG combined adjuvant; the final concentration of the CpG is 1 mM, and the final concentration of the PGPC is 25 µg / mL. The PGPC / CpG combined adjuvant can significantly promote the expression of the co-stimulating molecules CD40, CD80, CD86 on the surface of cDC1, and inflammatory factors IL-12, TNFɑ and IL-1β, enhance the ability of the cDC1 to induce CD8 + T cell activation, proliferation and differentiation into anti-tumor effector T cells, and effectively improve the in-vivo anti-tumor effect of the cDC1 vaccine.

In some embodiments, compositions and methods re¬lating to isolated artificial antigen presenting cells (aAPCs) are dis¬closed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A / B / C, ICOS-L, and CD58, and wherein the one or more viral vectors com¬prise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and / or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and / or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.

The present disclosure provides a novel technique relating to immunological tolerance. More specifically, the present inventor found for the first time that, in a technique for inducing immunological tolerance by administering to an organ transplantation patient (a recipient) a cell preparation containing cells in which anergy is induced by an inhibitor inhibiting the interaction between CD80 / CD86 and CD28, the immunological tolerance continues even after the disappearance of the cells derived from the cell preparation from the recipient (infectious immunological tolerance). Further, the present inventor proved that such a cell preparation can elicit immunological tolerance against immunological rejection caused by allergy, iPS cells, etc. or cells, tissues or organs derived therefrom.

Described herein is a method of isolating or enriching a population of cells for IL-10 producing type 2 innate lymphocytes, the method comprising: providing a population of cells comprising ILC2; cells expressing at least one of the following three markers: CD86, CD49d and retinoic acid related orphan alpha (RORA) are selected, and / or cells expressing GATA3 are rejected, including kits for implementing the methods. The use of isolated or enriched cell populations for cell therapy is also provided.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.

Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprising the same, and methods of using the same. The particle may be a lentiviral particle that displays on the surface of the particle a fusion molecule comprising: a) a CD58 extracellular domain, or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) a CD80 or CD86 extracellular domain, or a functional fragment thereof, and a viral glycoprotein (G protein).

The present invention relates to a reagent panels for the measurement of minimal residual disease (MRD) associated with pediatric B-cell precursor acute lymphoblastic leukemia (B- ALL) by multiparametric flow cytometry. The reagent panel of the invention comprises a combination of antibodies directed against markers, wherein the combination of antibodies comprises i) antibodies targeting markers CD45, CD20, CD34, CD38, CD10, CD58, CD66c, CD73, CD81, CD123, CD304, CD44, CD86, CD99 and CD371, and ii) antibodies targeting markers CD19 and / or CD22, wherein the antibodies are conjugated with fluorochromes. The invention further relates to the use of said panels for detecting MRD associated with B-ALL and / or for identifying a subject at risk of developing B-ALL relapse. The invention also relates to methods of detecting MRD associated with B-ALL. Key advantages of the invention include achieving high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity.

The invention discloses application of a CSF2RA gene, an acute myelogenous leukemia marker, a prognosis effect analysis model and a construction method thereof, and relates to the technical field of biology. Mainly relates to application of a reagent for detecting the expression quantity of a CSF2RA gene or a Hub gene related to the CSF2RA gene in preparation of a product for predicting the prognosis effect of acute myelogenous leukemia. Meanwhile, the invention also discloses an acute myelogenous leukemia marker which is one or more of CD4, ITGAM, TLR4, TLR2, FCGR3A, IL10, CD86, TLR8, ITGAX and FCGR2B genes. The invention provides a new target CSF2RA for predicting the prognosis effect of the acute myelogenous leukemia, and provides a prognosis effect analysis model, and the result shows that the high expression of the CSF2RA gene or the Hub gene related to the CSF2RA gene is related to the poor prognosis of a patient with the acute myelogenous leukemia.

The invention provides a monoclonal antibody targeting human HHLA2 and a multifunctional fusion antibody molecule derived from the monoclonal antibody, and relates to the field of biological medicine. The HHLA2 monoclonal antibody can be combined with an HHLA2 antigen with high specificity and effectively block an immunosuppression signal channel between the HHLA2 antigen and a receptor KIR3DL3, so that T cell function inhibition is relieved, and the tumor killing function of NK cells is promoted. Based on the antibody skeleton, a fusion antibody containing a plurality of immunomodulatory domains is constructed, and the domains include but are not limited to an anti-PD-L1 antibody or anti-PD-1 antibody or anti-CD3 antibody domain, a CD86 / CD80 variant polypeptide and an LAG3 variant polypeptide. The fusion antibody can cooperatively block a plurality of immune checkpoint pathways, activate a costimulatory signal, promote antigen presenting cell maturation, and enhance T cell activation and killing functions. The provided antibody molecule can be used for preparing immunotherapy drugs for various indications, is especially suitable for treating solid tumors or hematoma, and has remarkable application potential in the aspect of enhancing anti-tumor immune response.

The present invention relates to agents, uses and methods for treating cancer using agents for inhibiting IRF5 expression. Synergistic therapies include agents, uses, and methods for treating cancer using agents for inhibiting IRF5 expression in combination with agents for inhibiting TGF-beta2 expression. In some embodiments, one or more biomarkers, including one or more of IFNGR2, JAK1, and STAT1, and TGF-beta 2 and IRF5, TLR9, FOXP3, CCL22, CREB5, CD8a, CD86, CC14, CD163, ITGAX, and CD11c, can be used to select a subject that can benefit from the method, agent, or use. The agents and compositions may be used in combination with chemotherapy and other standard care therapies.

The application relates to an application of artemisinin in tolerance DC cell culture, and provides a tolerance DC cell culture medium with artemisinin, which comprises a basic culture medium, cytokines and artemisinin, wherein the concentration of the artemisinin is 0.5-5 muM. The tolerance DC cell culture medium with artemisinin has reduced expression levels of co-stimulating molecules CD80, CD83, CD86 and HLA-DR, which indicates that the addition of artemisinin is beneficial to the tolerance DC cell culture.

Provided are a tolerogenic DC cells culture medium and the use thereof in tolerogenic DC cells culturing. The culture medium comprises: a basic culture medium, a cytokine, berberine, and autologous plasma, wherein the concentration of berberine is 0.25-5 μM, and the cytokine comprises 100-1000 U / mL GM-CSF, 10-50 ng / mL IL -4, and 100-1000 U / mL TGF-β. The expression levels of costimulatory molecules CD80, CD83, CD86 and HLA-DR of DC cells cultured by means of the culture medium are significantly reduced.

The application discloses application of a plant-derived glycolipid in preparation of anti-inflammatory products, the inflammation is an inflammation reaction of RAW264.7 cells induced by LPS, and the plant-derived glycolipid realizes anti-inflammation by inhibiting expression of inflammatory factors. Through column chromatography combined with chromatographic analysis, the application realizes efficient extraction, accurate separation and structure identification of the plant GL, and provides important technical support for plant lipid research. The plant GL can significantly inhibit the inflammation reaction of RAW264.7 macrophages, including reducing LPS-induced cell morphological change, down-regulating mRNA expression of inflammatory factors and reducing expression level of CD86. The application provides a solid molecular level theoretical basis for application of the plant glycolipid in development of anti-inflammatory drugs.

The present invention discloses an antibody that specifically binds to human CTLA4, comprising three complementarily-determining regions; the three complementarity-determining regions are respectively: CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and CDR3 with an amino acid sequence as shown in SEQ ID NO: 3. Also disclosed are medicaments and kits comprising the antibodies described above. The antibodies of the present invention exhibit, but are not limited to, the following properties: (1) high affinity and specificity with human CTLA4; (2) able to block the interaction of CTLA4 with CD86 or CD80; (3) able to specifically bind to CTLA4 overexpressing cells; (4) enhancing activation of PBMC and / or T cells; (5) inhibiting tumor growth.